CLEARBRIDGE HEALTH LIMITED

(the "Company")

(Company Registration Number: 201001436C) (Incorporated in the Republic of Singapore)

EXTENSION OF TIME FOR HOLDING ANNUAL GENERAL MEETING FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2022

- 1. The Board of Directors (the "Board") of the Company refers to the Company's announcement dated 20 March 2023 (the "Announcement") relating to the extension of time for results announcement and holding of the annual general meeting ("AGM") for the financial year ended 31 December 2022 ("FY2022"). Unless otherwise defined, all capitalised terms in this announcement shall have the same definitions as ascribed to them in the Announcement.
- 2. The Board wishes to announce that the Company was informed on 5 April 2023 that the Accounting, Corporate and Regulatory Authority had, on 4 April 2023, granted approval for:
 - (a) a 60-day extension pursuant to Section 175 of the Companies Act 1967 of Singapore ("Companies Act"), to hold the AGM of the Company in relation to FY2022 ("FY2022 AGM"), and to lay the audited financial statements of the Company in relation to FY2022 ("FY2022 Financial Statements") before the Company at the AGM by 29 June 2023; and
 - (b) a 60-day extension pursuant to Section 197 of the Companies Act, to lodge the annual return of the Company in relation to FY2022 by 30 July 2023.
- 3. The Company will make the necessary announcements to update shareholders on the outcome of its application to the Singapore Exchange Securities Trading Limited ("SGX-ST") to seek:
 - (a) a three-month extension of the deadline under Rule 705(1) of the Listing Manual Section B: Rules of Catalist of the SGX-ST (the "<u>Catalist Rules</u>"), to announce the FY2022 Financial Statements by 31 May 2023; and
 - (b) a 60-day extension of the deadline under Rule 707(1) of the Catalist Rules, to hold the FY2022 AGM by 29 June 2023.

BY ORDER OF THE BOARD

Yee Pinh Jeremy

Executive Director and Chief Executive Officer

6 April 2023

This announcement has been prepared by the Company and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with Rules 226(2)(b) and 753(2) of the Catalist Rules. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr David Tham, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.